Last reviewed · How we verify
Primary hyperoxaluria, type I
Approved treatments
- Oxlumo · Alnylam Pharmaceuticals
Oxlumo works by binding to and silencing the mRNA that produces the enzyme Hydroxyacid oxidase 1, which is overactive in patients with Primary hyperoxaluria, type I.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Primary hyperoxaluria, type I patent landscape — cliff calendar, originator estates, attackable patents
- Primary hyperoxaluria, type I treatment landscape brief
- Primary hyperoxaluria, type I treatment updates RSS
Frequently asked questions about Primary hyperoxaluria, type I
What drugs treat Primary hyperoxaluria, type I?
Tracked treatments include Oxlumo.
What is the treatment for Primary hyperoxaluria, type I?
Standard treatment for Primary hyperoxaluria, type I includes Oxlumo. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Primary hyperoxaluria, type I patent cliff · Primary hyperoxaluria, type I CI report
- Treatment: Oxlumo · Alnylam Pharmaceuticals
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing